Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.37 |
| ▸ | PIM1 | P11309 | 3/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17619980 | 0.82 | TRPA1 (0.40) | PIM1PIM3PIM2ALOX5APFEN1 | |
| SCHEMBL17609542 | 0.82 | SMPD3 (0.40) | SMPD3MAP3K12BTK | |
| SCHEMBL17609930 | 0.81 | MAP3K12 (0.43) | SMPD3MAP3K12BTK | |
| SCHEMBL17609994 | 0.80 | PIM1 (0.33) | SMPD3MAP3K12PIM1PIM3PIM2 | |
| SCHEMBL31015574 | 0.78 | SMPD3 (0.45) | SMPD3MAP3K12RBP4 | |
| SCHEMBL17609917 | 0.75 | MAP3K12 (0.43) | SMPD3MAP3K12BTK | |
| SCHEMBL21861605 | 0.75 | PIM1 (0.31) | PIM1PIM3PIM2ALOX5APFEN1 | |
| SCHEMBL17609717 | 0.75 | SMPD3 (0.36) | SMPD3MAP3K12BTK | |
| SCHEMBL22795652 | 0.68 | CHRNB4 (0.38) | SMPD3 | |
| SCHEMBL17609552 | 0.67 | TRPA1 (0.37) | SMPD3MAP3K12PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193880-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3193880-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2019-10-31 | — | — | US | disclosed |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2019-10-31 | — | — | US | disclosed |
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | HYDRA BIOSCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | HYDRA BIOSCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| EP-3193880-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | Hydra Biosciences, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044792-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044792-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPV1, TRPA1, TRPV2 | SMPD3 2344/4885MAP3K12 2163/4885PIM1 4645/4885 |
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPV1, TRPA1, TRPV2 | SMPD3 2344/4885MAP3K12 2163/4885PIM1 4645/4885 |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPV1, TRPA1, TRPV2 | SMPD3 2344/4885MAP3K12 2163/4885PIM1 4645/4885 |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPV1, TRPA1, TRPV2 | SMPD3 2344/4885MAP3K12 2163/4885PIM1 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.